Immune phenotype-guided identification of disease-associated pathobionts in Crohn’s disease

Hiroko Nagao‐Kitamoto, Kohei Sugihara, Sho Kitamoto, Shinya Ebihara, Yeji Kim, Kira L. Newman, Uxía Alonso Alonso, Takehiro Suzuki, Yoshiyuki Kioi, Arash Yunesi, Naohiro Inohara, Christopher J. Alteri, Phillip Minar, Lee A. Denson, Peter Higgins, John Y. Kao, Shrinivas Bishu, Yuying Xie, Yu L. Lei, Nobuhiko KamadabioRxiv 2025 · DOI

TL;DR

Researchers have identified specific Escherichia coli strains, termed "IL-1β-inducing pathobionts" (IBIPs), that contribute to Crohn's disease (CD) inflammation by triggering a key immune pathway. These IBIPs can be detected via stool IgA levels, potentially serving as a biomarker to predict treatment response in CD patients.

What Problem Does This Paper Address?

Crohn's disease (CD) is a chronic inflammatory bowel disease with a complex etiology, where gut dysbiosis (an imbalance in gut bacteria) is strongly implicated. However, the specific bacteria driving this inflammation and the precise immune responses they trigger remain poorly understood. This knowledge gap hinders the development of targeted therapies and accurate patient stratification. This paper aims to identify specific "pathobionts" (microbes that can cause disease under certain conditions) in CD patients and elucidate their role in immune activation and disease pathogenesis.

Methods

The study employed a multi-pronged approach:

  • Human Microbiota-Associated (HMA) Mouse Model: Germ-free mice were colonized with gut microbiota from CD patients or healthy controls to mimic human gut environments and study immune responses.
  • Single-Cell RNA Sequencing (scRNA-Seq): This technique allowed for a detailed analysis of individual immune cells in the colons of HMA mice, identifying specific cell populations and their gene expression patterns.
  • Bacterial Isolation and Characterization: Bacteria from CD patient-derived HMA mice were isolated and cultured. Their ability to induce IL-1β (a key inflammatory cytokine) was tested. Genomic analysis was performed to identify virulence genes and phylogenetic relationships.
  • In Vitro and In Vivo Assays: Isolated bacterial strains were used to stimulate immune cells in culture (BMDMs and colonic LPMCs) to measure cytokine production. An animal model of colitis (DSS-induced) was used to assess the impact of IBIP colonization on disease severity, with and without IL-1 receptor blockade (Anakinra).
  • Biomarker Development: Fecal samples from human patients were analyzed for immunoglobulin A (IgA) levels specific to IBIPs to assess colonization and correlate it with disease activity and treatment response.

Datasets

  • Human Stool Samples: Collected from healthy control (HC) subjects and patients with Crohn's disease (CD). These were used for HMA mouse colonization and for measuring fecal IgA levels.
  • Mouse Microbiome Data: Generated from HMA mice colonized with human microbiota.
  • Single-cell RNA Sequencing Data: From colonic lamina propria cells of HMA mice.
  • Bacterial Genomic Data: From isolated IBIP strains and reference E. coli strains.

Key Insights and Ideas

  • IBIPs as Key Drivers of Inflammation: The study identified specific E. coli strains (IBIPs) that are enriched in CD patients and potently induce IL-1β, a crucial cytokine in CD pathogenesis. This moves beyond general dysbiosis to pinpoint specific microbial culprits.
  • IL-1β Pathway as a Central Hub: The research strongly implicates the IL-1β signaling pathway as a critical mediator of CD-associated inflammation, driven by these IBIPs. Blocking this pathway showed therapeutic potential in animal models.
  • IBIPs as Potential Biomarkers: The discovery that IBIP colonization can be detected by measuring specific IgA levels in stool is a significant breakthrough. This opens the door for non-invasive diagnostics.
  • Predicting Treatment Response: The correlation between high IBIP-reactive IgA levels and refractoriness to anti-TNF therapies suggests that IBIP colonization could predict which patients are unlikely to benefit from these standard treatments, allowing for earlier consideration of alternative therapies.

Key Results

  • CD-associated microbiota in HMA mice led to an accumulation of IL-1β-producing mononuclear phagocytes (MNPs), driving an IL-1-driven inflammatory signature.
  • Three E. coli strains (HK1, HK2, HK7), termed IBIPs, were identified as potent inducers of IL-1β but not IL-10. These strains were absent in healthy controls.
  • IBIP E. coli strains possess unique virulence genes and exacerbated experimental colitis in mice in an IL-1-dependent manner.
  • Approximately 55% of CD patients tested positive for IBIP HK7-reactive IgA, suggesting widespread colonization.
  • High levels of IBIP HK7-reactive IgA in treatment-naïve pediatric CD patients were associated with refractoriness to anti-TNF therapies, while low levels predicted response.

Limitations and Future Work

  • Mouse Model Limitations: While the HMA mouse model is valuable, it doesn't perfectly replicate the complexity of the human gut microbiome and immune system.
  • Generalizability of Biomarker: The study's pilot nature with a small cohort of pediatric patients means larger, diverse patient cohorts are needed to validate IBIP-reactive IgA as a predictive biomarker for anti-TNF therapy response.
  • Specificity of Virulence Genes: The exact virulence genes responsible for IBIPs' potent IL-1β induction require further investigation.
  • Therapeutic Targeting: While IL-1 signaling blockade showed promise, the study acknowledges that IL-1β can also play a role in epithelial barrier integrity, suggesting that therapies targeting this pathway may not be universally beneficial for all CD patients. Future work should explore the precise patient subgroups that would benefit most from IL-1-targeted therapies versus anti-TNF treatments. The authors suggest developing targeted therapies to decolonize IBIPs.

Summary updated

Abstract

Summary Aberrant immune activation within the gut mucosa and gut dysbiosis have been implicated in the pathogenesis of Crohn’s disease (CD). However, the specific immune responses triggered by dysbiotic microbiota, as well as the bacteria responsible for this activation, remain incompletely understood. Here, using the human microbiota-associated (HMA) mouse system, we demonstrated that colonization with dysbiotic gut microbiota from CD patients specifically induces the accumulation of mononuclear phagocytes, which may drive an interleukin-1 (IL-1)-driven inflammatory signature. Moreover, we identified pathobiont strains with a potent IL-1β-inducing capacity, termed ‘IL-1β-inducing pathobionts’ (IBIP). Isolated IBIP strains exhibit genetic and functional similarities to adherent-invasive Escherichia coli but harbor unique virulence-associated genes. Colonization with the IBIP E. coli strain exacerbated experimental colitis in an IL-1 signal-dependent manner. Notably, the colonization of IBIP E. coli can be detected by measuring the levels of specific immunoglobulin A (IgA) in their stool samples. Moreover, the level of IBIP-reactive IgA in stool may serve as a predictive biomarker for treatment response to anti-TNF therapies in treatment-naïve pediatric CD patients. Altogether, IBIP colonization could help identify CD patients with inflammatory dysbiosis who are likely to be refractory to anti-TNF therapies.
BibTeX
@misc{nagaokitamoto2025immune,
  author = {Hiroko Nagao‐Kitamoto and Kohei Sugihara and Sho Kitamoto and Shinya Ebihara and Yeji Kim and Kira L. Newman and Uxía Alonso Alonso and Takehiro Suzuki and Yoshiyuki Kioi and Arash Yunesi and Naohiro Inohara and Christopher J. Alteri and Phillip Minar and Lee A. Denson and Peter Higgins and John Y. Kao and Shrinivas Bishu and Yuying Xie and Yu L. Lei and Nobuhiko Kamada},
  title = {{Immune phenotype-guided identification of disease-associated pathobionts in Crohn’s disease}},
  year = {2025},
  doi = {10.1101/2025.04.01.646605},
  howpublished = {bioRxiv},
}
Figure